HilleVaxHLVX
Market Cap: $90.1M
About: HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
Employees: 90
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
250% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 12
85% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 13
14% more funds holding
Funds holding: 80 [Q1] → 91 (+11) [Q2]
3.04% more ownership
Funds ownership: 74.93% [Q1] → 77.97% (+3.04%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 5 [Q1] → 5 (+0) [Q2]
10% less capital invested
Capital invested by funds: $619M [Q1] → $560M (-$58.9M) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
HC Wainwright & Co. Matthew Caufield 42% 1-year accuracy 15 / 36 met price target | 11%upside $2 | Neutral Reiterated | 12 Aug 2024 |
Leerink Partners David Risinger 100% 1-year accuracy 6 / 6 met price target | 11%upside $2 | Market Perform Downgraded | 9 Jul 2024 |
Stifel Stephen Willey 40% 1-year accuracy 6 / 15 met price target | 66%upside $3 | Hold Downgraded | 9 Jul 2024 |
Financial journalist opinion
Based on 6 articles about HLVX published over the past 30 days